Skip to content

EnZeta Immunotherapies

2 viewers · 30d

Total raised

$840K

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $840K
ROUNDS
1
INVESTORS
10
FOUNDED
2023
HQ
Coral Gables, FL
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

EnZeta Immunotherapies is an early-stage biotechnology company founded in 2023 and headquartered in Coral Gables, Florida. The company focuses on developing and commercializing T-cell-based immunotherapies for the treatment of solid tumors. Its core strategy is built upon an exclusive patent license secured from the National Institutes of Health (NIH).

What sets it apart

The company's primary strategic asset is its exclusive patent license from the NIH, providing it with foundational intellectual property to develop novel T-cell therapies for solid tumors.

Funding history

1 round
Equity+2Feb 17, 2025
Form D/A
+$840K$840K total

Latest SEC filings

via EDGAR · CIK 0001994145
Form D/A · Feb 17, 2025View on EDGAR

Products

1 tracked

T-cell-based Immunotherapies for Solid Tumors

Cancer Immunotherapy

The company is developing treatments that use a patient's own T cells, which are engineered to recognize and attack specific proteins on the surface of solid tumor cells. This therapeutic approach is based on technology covered by an exclusive patent license from the National Institutes of Health.

  • Engineered T-cell technology
  • Targeted treatment for solid tumors
  • Leverages government-backed intellectual property

Links

SEC EDGAR filings